First eye patient receives synthetic cornea

For the first time in Utrecht, a synthetic cornea was transplanted into a patient with a complex eye condition. The artificial cornea is an interesting alternative due to the donor shortage, and is a prelude to regenerative corneal transplants with cultured cells.
‘With my research, I am pushing for these types of implants to become regenerative. That means they will also contain cells and thus actually repair the cornea. The current synthetic implant can be a prelude to that, because this kind of material can also be the carrier of those cells,’ said UMC Utrecht professor of ophthalmology Mor Dickman, who recently performed the transplant with the synthetic cornea.
Major shortage of donor corneas
About 2,000 cornea transplants take place in the Netherlands every year, making it the most frequently performed transplant. Many of the recipients of such a transplant are elderly people, but younger patients and children also sometimes receive a cornea. Unfortunately, there is a huge shortage of donor corneas: there is about 1 donor for every 70 patients.
Corneal transplantation at UMC Utrecht.
An alternative graft
Because of the donor shortage, there is a great drive to find alternatives. It is the personal motivation of Professor of Ophthalmology Mor Dickman, who is now placing a synthetic corneal transplant in Utrecht for the first time. ‘This implant is made of a kind of contact lens material,’ he explains. ‘In this case, it replaces the inner part of the cornea.’
In the Netherlands, this technique is particularly interesting for patients with a high risk of rejection or graft failure. Mor: ‘These include patients with multiple previous transplants, a history of rejection, or after glaucoma surgery where small tubes are placed in the eye. There are also patients who do not want to receive donor tissue for cultural or religious reasons, and then this can be an alternative.’
Towards regenerative treatment
The synthetic implant was developed by a company, Eye-Yon. ‘Currently, we only apply this technique to the most complex cases,’ says Mor. ‘With further refinement and development, this technique could be a solution for a wider patient group in the future.’ An additional advantage is that a synthetic implant presents much less logistical challenges than a donated cornea.
In the further future, Mor sees other developments ahead. ‘With my research, I am pushing for these kinds of implants to become regenerative. That means they will also contain cells and thus actually repair the cornea. The current synthetic implant can be a prelude to that, because this kind of material can also be the carrier of those cells.’

Utrecht Science Week: Boudewijn Visscher on the Future of Washable Incontinence Materials
In the Netherlands, approximately 85 million kilograms of waste from incontinence materials are generated every year. Washable alternatives could help reduce this waste stream, but switching to washable materials is not yet common practice in healthcare. What is holding back this transition, and what is needed to make washable incontinence materials more widely applicable?

Utrecht Science Week: René van Westen on a colder Netherlands in a warmer world
The Earth is warming, yet the Netherlands could face much colder winters in the future. It may sound contradictory, but the explanation lies in the Atlantic Meridional Overturning Circulation (AMOC), a large system of ocean currents that transports heat and salt through the Atlantic Ocean. This circulation plays an important role in the mild climate that we are accustomed to in the Netherlands.

Opening Utrecht Science Week with keynote by Juliette Legler on the hidden influence of environmental chemicals
On Friday, September 25, the annual science festival ‘Utrecht Science Week’ kicks off once again at Utrecht Science Park. We are pleased to announce that this year, Prof. Dr. Ir. Juliette Legler will deliver the Utrecht Science Lecture. Juliette Legler is Professor of Toxicology at the Faculty of Veterinary Medicine at Utrecht University and leads the ‘One Health Toxicology’ group at the Institute for Risk Assessment Sciences (IRAS).
